The MEAI-based proprietary compound is aimed at treating Alcohol Use Disorder Tel Aviv, Israel / Vancouver, Canada, Dec. 13, 2022 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq,CSE: CMND), (FSE: CWY) (“ Clearmind” or the “company“), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under treated health problems…
Source